Use of Gabapentin for Conversion Disorder: Three Case Reports
Keywords:
Conversion Disorder, Gabapentin, Psychogenic seizureAbstract
Conversion disorder is an illness that often manifest after a stressful life event, trauma, or psychological distress. It persists for many years in majority of cases and in some cases, the prognosis is very poor. Conversion disorder causes clinically significant impairment in occupational, social, or other important areas of functioning and the healthcare cost associated with it can be very high, yet there is no specific pharmacological therapy for its management in clinical settings. The aim of this article is to present three cases of middle-aged women with conversion disorder treated with Gabapentin. The use of Gabapentin has not been studied in controlled trials for the treatment of conversion symptoms, particularly in the absence of epileptic seizures. Most studies have focussed on use of antidepressants, particularly Selective Serotonin Reuptake Inhibitors (SSRIs) in the treatment of conversion disorder. Previous studies have also linked anticonvulsant with pseudoseizures. However, in these three cases, Gabapentin was well tolerated and health improvement was observed following the administration of Gabapentin 300mg oral twice daily, and in one of the cases, the conversion symptoms vanished completely after optimized to 600mg oral twice daily. The conclusion is that
References
Ali, S., Jabeen, S., Jabeen, S., Shahid, M., Chinala, S., Nathani, M., et al. (2015) Conversion Disorder- Mind versus Body: A Review. Innov Clin Neurosci, 12(5-6): 27-33.
Ludwig, L., Pasman, JA., Nicholson, T., Aybek, S., David, AS., Tuck, S., et al. (2018) Stressful life events and maltreatment in conversion (functional neurological) disorder: systematic review and meta-analysis of case-control studies. Lancet Psychiatry, 5(4): 307-320.
Bennett, K., Diamond, C., Hoeritzauer, I., Gardiner, P., McWhirter, L., Carson, A., et al. (2021) A practical review of functional neurological disorder (FND) for the general physician. Clin Med (Lond), 21(1): 28-36.
Espay, AJ., Aybek, S., Carson, A., Edwards, MJ., Goldstein, LH., Hallett, M., et al., (2018) Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. JAMA Neurol, 75(9): 1132-1141.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental disorders, 5th ed (DSM-5). Washington, DC, American Psychiatric Association, 2013.
Blitzstein, SM. (2008) Recognizing and treating conversion disorder. Virtual Mentor, 10(3): 158-160.
Ejareh Dar, M., Kanaan, RA. (2016) Uncovering the etiology of conversion disorder: insights from functional neuroimaging. Neuropsychiatr Dis Treat, 12: 143-153.
Carson, A., Stone, J., Hibberd, C., Murray, G., Duncan, R., Coleman, R., et al. (2011) Disability, distress and unemployment in neurology outpatients with symptoms ‘unexplained by organic disease’. J Neurol Neurosurg Psychiatry, 82(7): 810–813.
Stone, J., Hoeritzauer, I., Brown, K., Carson, A. (2014) Therapeutic sedation for functional (psychogenic) neurological symptoms. J Psychosom Res, 76(2): 165-168.
Gelauff, J., Stone, J. (2016) Prognosis of functional neurologic disorders. Handb Clin Neurol, 139: 523-541.
Stephen, CD., Fung, V., Lungu, CI., Espay, AJ. (2021) Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders. JAMA Neurol, 78(1): 88-101.
Stone, J., Sharpe, M., Dimsdale, J., Solomon, D. (2022) Conversion disorder in adults: Epidemiology, pathogenesis, and prognosis, UpToDate, 2022, Accessed 30th December 2022.
Feinstein, A. (2011) Conversion disorder: advances in our understanding. CMAJ, 183(8): 915-920.
Whiting, DL., Riashi, M., Perry, KN. (2019) A clinician's quick guide of evidence-based approaches: Functional neurological symptom disorder (conversion disorder). Clinical Psychologist, 23(2): 177-179.
Stonnington, CM., Barry, JJ., Fisher, RS. (2006) Conversion Disorder. Am J Psychiatry, 163(9): 1510-1517.
LaFrance, WC., Devinsky, O. (2004) The treatment of nonepileptic seizures: historical perspectives and future directions. Epilepsia, 2(45 suppl): 15–21.
Voon, V., Lang, AE. (2005) Antidepressant treatment outcomes of psychogenic movement disorder. J Clin Psychiatry, 66(12): 1529-1534.
LaFrance, WC., Barry, JJ. (2005) Update on treatments of psychological nonepileptic seizures. Epilepsy Behav, 7(3): 364–374.
Marazziti. D., Dell’Osso, B. (2005) Effectiveness of risperidone in psychogenic stiff neck. CNS Spect, 10(6): 443– 444.
Prigatano GP., Stonnington CM., Fisher, RS. (2002) Psychological factors in the genesis and management of nonepileptic seizures: clinical observations. Epilepsy Behav, 3(4): 343–349.
Messina, A., Fogliani, AM. (2010) Valproate in Conversion Disorder: A Case Report. Case Rep Med, 1-3.
Tripathi, KD. (2013) Essentials of medical pharmacology (7th ed), Jaypee Brothers Medical Publishers (P) Ltd: New Delhi.
Fukuchi, T., Ishida, S., Kato, M., Onuma, T. (1995) [Seven cases of pseudoseizure unnecessarily treated with AEDs]. No To Shinkei, 47(3): 239-244.
Weaver, DF. (2004) “Organic” pseudoseizures as an unrecognized side-effect of anticonvulsant therapy. Seizure, 13(7): 467-469.
